$1.550
+0.052 (+3.33%)Zum Schluss
BGLC-News
BGLC-Events
BioNexus Gene Lab Appoints Dr. Muthu Meyyappan as Chief Commercial Officer
BioNexus Gene Lab announced that, in connection with its Fidelion Diagnostics transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Dr. Meyyappan will lead Fidelion's global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations to support the adoption of advanced oncology diagnostic technologies across international markets. Most recently, Dr. Meyyappan served as CCO at Menarini Silicon Biosystems, where he helped expand the company's oncology diagnostics business and supported the commercial adoption of liquid biopsy and MRD-related diagnostic platforms.
BioNexus Completes Governance Restructuring of Chemrex Corporation
BioNexus Gene Lab announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation. As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew Barsing, Chairman; Angeline Chong, Chief Financial Officer of BioNexus, Director. New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates under the oversight framework of the BioNexus Board of Directors and its committees.
BioNexus Gene Lab Officially Launches VitaGuard 2026 Deployment Phase
BioNexus Gene Lab announced the formal commencement of its 2026 Deployment Phase for the VitaGuard Minimal Residual Disease platform. This phase marks the transition of VitaGuard from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026.
BioNexus Gene Lab Completes Strategic Transaction with Fidelion Diagnostics
BioNexus Gene Lab announced the completion of its strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard Tumor-Naive Minimal Residual Disease liquid biopsy platform across Southeast Asia. BGLC has acquired a 15% equity position in Fidelion Diagnostics, the company that holds the exclusive global commercial rights to the VitaGuard Tumor-Naive AI-oncology platform. This investment provides BGLC shareholders with direct participation in Fidelion's international expansion and future capital markets trajectory, including potential private financing rounds or a future "Qualified Financing Event," which the agreements specifically include listing on Nasdaq or NYSE as options. Simultaneously, BGLC has obtained exclusive, perpetual rights to manufacture, market, and distribute VitaGuard across all ASEAN markets, solidifying the Company as the sole provider of this advanced liquid biopsy technology in one of the world's fastest-growing oncology regions.
BioNexus Enters $500M Equity Purchase Agreement with ARC Group International
BioNexus Gene Lab entered into a $500,000,000 Equity Purchase Agreement with ARC Group International.The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard minimal residual disease platform, the addition of contract development and manufacturing organization services to its business regionally, and building the Company's therapeutic development and commercialization programs. Under the terms of the Agreement, BGLC, at its sole discretion, may issue and sell registered shares of its common stock to ARC over the commitment period of 36 months. In consideration for ARC's commitment, BGLC issued 175,000 shares of common stock as a one-time fee, priced at the closing price on Nov 26, 2025 - $4.32. ARC is prohibited from owning more than 9.99% of BGLC's outstanding shares at any time and is restricted from short-selling or hedging the Company's securities. The Company will file a registration statement to register the resale of shares issued under the Facility, and no shares may be sold prior to registration. The Facility complements BGLC's previously announced $20M At-The-Market program, enhancing the Company's financial flexibility while preserving strategic control over the timing and scale of capital deployment.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.